BiomX (PHGE) Other Non-Current Assets (2018 - 2025)
BiomX (PHGE) posted Other Non-Current Assets of $595000.0 for Q4 2025, up 269.57% sequentially from $161000.0 in Q3 2025, and down 46.83% YoY from $1.1 million in Q4 2024.
BiomX (PHGE) Other Non-Current Assets (2018 - 2025) Analysis & Trends
BiomX has reported Other Non-Current Assets for 8 years, with the latest figure at $595000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 46.83% year-over-year to $595000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $595000.0 (down 46.83% YoY) and the FY2025 annual result came in at $595000.0, down 46.83% from the prior year.
- Other Non-Current Assets rose to $595000.0 in Q4 2025 per PHGE's latest filing, from $161000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $5.0 million in Q4 2021 and troughed at $5000.0 in Q3 2021.
- A 5-year average of $762000.0 and a median of $298500.0 in 2022 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 3446.1% in 2021, down 99.85% in 2021.
- Over 5 years, Other Non-Current Assets stood at $5.0 million in 2021, then slumped by 91.28% to $436000.0 in 2022, then advanced by 13.53% to $495000.0 in 2023, then jumped by 126.06% to $1.1 million in 2024, then tumbled by 46.83% to $595000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $595000.0, $161000.0, and $161000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 892,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Dec 31, 2023 | 495,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 436,000.00 |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 5,000.00 |
| Dec 31, 2020 | 141,000.00 |
| Sep 30, 2020 | 3.42 Mn |
| Jun 30, 2020 | 3.80 Mn |
| Mar 31, 2020 | 5,000.00 |
| Dec 31, 2019 | 4.56 Mn |
| Dec 31, 2018 | 4.56 Mn |